CN102361857B - 可用作抗糖尿病剂的环状苯并咪唑衍生物 - Google Patents

可用作抗糖尿病剂的环状苯并咪唑衍生物 Download PDF

Info

Publication number
CN102361857B
CN102361857B CN200980147275.5A CN200980147275A CN102361857B CN 102361857 B CN102361857 B CN 102361857B CN 200980147275 A CN200980147275 A CN 200980147275A CN 102361857 B CN102361857 B CN 102361857B
Authority
CN
China
Prior art keywords
alkyl
phenyl
unsubstituted
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980147275.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102361857A (zh
Inventor
B.C.布克塞尔
Q.党
T.S.吉布森
H.姜
D.M.钟
J.鲍
J.姜
A.凯西克
A.凯克
P.兰
H.卢
G.M.马卡拉
F.A.罗梅罗
I.塞巴特
D.威尔逊
D.沃卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Schering Corp filed Critical Metabasis Therapeutics Inc
Publication of CN102361857A publication Critical patent/CN102361857A/zh
Application granted granted Critical
Publication of CN102361857B publication Critical patent/CN102361857B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200980147275.5A 2008-09-26 2009-09-21 可用作抗糖尿病剂的环状苯并咪唑衍生物 Active CN102361857B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19433708P 2008-09-26 2008-09-26
US61/194337 2008-09-26
PCT/US2009/057686 WO2010036613A1 (en) 2008-09-26 2009-09-21 Novel cyclic benzimidazole derivatives useful anti-diabetic agents

Publications (2)

Publication Number Publication Date
CN102361857A CN102361857A (zh) 2012-02-22
CN102361857B true CN102361857B (zh) 2015-09-16

Family

ID=41395799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980147275.5A Active CN102361857B (zh) 2008-09-26 2009-09-21 可用作抗糖尿病剂的环状苯并咪唑衍生物

Country Status (10)

Country Link
US (1) US8394969B2 (enExample)
EP (1) EP3924343A1 (enExample)
JP (1) JP5764064B2 (enExample)
CN (1) CN102361857B (enExample)
AR (1) AR073677A1 (enExample)
AU (1) AU2009296820B2 (enExample)
CA (1) CA2737694C (enExample)
MX (1) MX2011003239A (enExample)
TW (1) TWI393709B (enExample)
WO (1) WO2010036613A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004258A (es) * 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
MX2011004505A (es) 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2679918T3 (es) 2010-02-18 2018-08-31 Vtv Therapeutics Llc Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos
CA2786314A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8344137B2 (en) * 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives
RU2635662C2 (ru) 2010-09-10 2017-11-15 Сионоги Энд Ко., Лтд. Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием
WO2012047772A2 (en) * 2010-10-07 2012-04-12 Schering Corporation Imidazole derivatives
WO2012064569A1 (en) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Imidazole derivatives
FR2968213B1 (fr) 2010-12-03 2014-03-21 Oreal Utilisation d'une association amincissante
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
SG192941A1 (en) * 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CA2837312A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
CN103781786A (zh) 2011-07-15 2014-05-07 盐野义制药株式会社 具有ampk活化作用的氮杂苯并咪唑衍生物
TWI449702B (zh) * 2012-07-11 2014-08-21 Merck Sharp & Dohme 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
JP2015526468A (ja) * 2012-08-22 2015-09-10 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 新規なアザベンズイミダゾールヘキサヒドロフロ[3,2−b]フラン誘導体
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives
EP2887807B1 (en) * 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators
CA2903657A1 (en) 2013-02-27 2014-09-04 Shionogi & Co., Ltd. Indole and azaindole derivatives each having ampk-activating activity
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2747973T3 (es) 2013-11-15 2020-03-12 Merck Sharp & Dohme Compuestos tricíclicos antidiabéticos
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
WO2016031842A1 (ja) 2014-08-27 2016-03-03 塩野義製薬株式会社 Ampk活性化作用を有するアザインドール誘導体
CA2965781A1 (en) * 2014-10-28 2016-05-06 Shionogi & Co., Ltd. Heterocyclic derivative having ampk activating effect
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN104961703A (zh) * 2015-07-14 2015-10-07 佛山市赛维斯医药科技有限公司 一类苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途
CN104961702A (zh) * 2015-07-14 2015-10-07 佛山市赛维斯医药科技有限公司 苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途
CN105596333A (zh) * 2016-02-02 2016-05-25 白强 一种防治糖尿病及其并发症的药物组合物及其应用
EP3421467A4 (en) 2016-02-26 2019-08-07 Shionogi & Co., Ltd 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATION EFFECT
EP3459949A4 (en) 2016-05-20 2020-04-08 Shionogi & Co., Ltd 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT
US11174246B2 (en) * 2016-08-19 2021-11-16 Rigel Pharmaceuticals, Inc. Direct AMPK activators
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
CN108503632B (zh) * 2018-06-26 2020-07-28 北京圣永制药有限公司 一种吲哚类衍生物及其在糖尿病中的应用
AU2020259143A1 (en) 2019-04-19 2021-11-11 Assistance Publique Hopitaux De Paris pl6INK4a inhibitor for preventing or treating Huntington's disease
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
MX2022009898A (es) * 2020-02-13 2022-08-25 Genfleet Therapeutics Shanghai Inc Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
JP7745559B2 (ja) 2020-02-28 2025-09-29 キャリーオペ,インク. Gpr40アゴニスト
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ,インク. Ampkアクチベーター
WO2023092094A2 (en) 2021-11-19 2023-05-25 The Broad Institute, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof
TW202329944A (zh) * 2021-11-23 2023-08-01 美商克力歐普股份有限公司 Ampk活化劑
CN117050043A (zh) * 2022-05-13 2023-11-14 中国海洋大学 一种3-苯基二苯并呋喃类化合物及其制备方法和用途
CN117243950A (zh) * 2023-10-31 2023-12-19 首都医科大学附属北京朝阳医院 Mk-3903在制备预防和/或治疗缺血性心脏病的药物中的应用
WO2025101276A1 (en) * 2023-11-06 2025-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for making and using immune cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236267A1 (en) * 2002-05-14 2003-12-25 Kensuke Kobayashi Benzimidazole derivatives
US20040044056A1 (en) * 2000-11-15 2004-03-04 Osamu Okamoto Benzimidazole derivatives
CN1829713A (zh) * 2003-07-30 2006-09-06 辉瑞大药厂 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2472574A1 (fr) * 1979-12-24 1981-07-03 Ici Pharma Derives de cephalosporine et composition pharmaceutique les contenant
JPS57151944A (en) 1981-03-16 1982-09-20 Fuji Photo Film Co Ltd Color photosensitive silver halide material
JPS58193541A (ja) 1982-05-07 1983-11-11 Konishiroku Photo Ind Co Ltd 熱現像画像記録材料
JPH0245181B2 (ja) 1983-03-16 1990-10-08 Fuji Photo Film Co Ltd Netsugenzokaraakankozairyo
GB8313321D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Preparation of mercaptan substituted carboxylic acids
GB8313320D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Coating compositions
GB8313322D0 (en) 1983-05-14 1983-06-22 Ciba Geigy Ag Heterocyclic-(cyclo)aliphatic carboxylic acids
GB8412063D0 (en) 1984-05-11 1984-06-20 Ciba Geigy Ag Compositions containing heterocyclic corrosion inhibitors
GB8412065D0 (en) 1984-05-11 1984-06-20 Ciba Geigy Ag Preparation of carboxylic acid derivatives
GB8412064D0 (en) 1984-05-11 1984-06-20 Ciba Geigy Ag Compositions containing heterocyclic corrosion inhibitors
GB8525452D0 (en) * 1985-10-16 1985-11-20 Fisons Plc Biologically active nitrogen heterocycles
ES2052544T3 (es) * 1986-02-03 1994-07-16 Janssen Pharmaceutica Nv Composiciones anti-histaminicas que contienen n-heterociclil-4-piperidinaminas.
JPH01501473A (ja) * 1986-09-27 1989-05-25 フアイソンズ・ピーエルシー 化合物
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
CA1317939C (en) * 1987-07-01 1993-05-18 Janssen Pharmaceutica Naamloze Vennootschap ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5559127A (en) 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH06298731A (ja) 1993-04-13 1994-10-25 Fuji Photo Film Co Ltd 複素環化合物の製造方法
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
CA2170375A1 (en) * 1994-06-30 1996-01-11 Sourav K. Kundu Bioactive porous partition members
JPH09227854A (ja) 1996-02-26 1997-09-02 Toyo Ink Mfg Co Ltd 感エネルギー線酸発生剤、感エネルギー線酸発生剤組成物、硬化性組成物およびその硬化物
AU717430B2 (en) 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ID24054A (id) 1997-06-10 2000-07-06 Glaxo Group Ltd Glaxo Turunan turunan benzimidazol
EA200000873A1 (ru) 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипазы a
JP4741725B2 (ja) 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU758789B2 (en) 1998-07-15 2003-03-27 Teijin Limited Thiobenzimidazole derivatives
PL205184B1 (pl) 1998-09-09 2010-03-31 Metabasis Therapeutics Inc Nowe heteroaromatyczne inhibitory 1,6-bisfosfatazy fruktozy, kompozycje farmaceutyczne zawierające te związki i ich zastosowanie
SE9900211D0 (sv) * 1999-01-25 1999-01-25 Pharmacia & Upjohn Ab New compounds
HK1043796B (en) 1999-03-05 2007-02-23 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrugs
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU783839B2 (en) 2000-01-17 2005-12-15 Teijin Limited Human chymase inhibitors
DE60130865T2 (de) 2000-01-17 2008-07-17 Teijin Pharma Ltd. Benzimidazol-derivate als menschliche chymase - inhibitoren
EP1681287A1 (en) * 2000-07-04 2006-07-19 Ube Industries, Ltd. Benzoxazole compounds, process for producing the same, and herbicides
JP4734705B2 (ja) 2000-10-31 2011-07-27 三菱化学株式会社 リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
WO2003018061A1 (en) 2001-08-24 2003-03-06 Teijin Limited Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
FR2829765A1 (fr) 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
SE0104331D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
FR2846656B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CA2524436A1 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
JP2007521296A (ja) 2003-07-01 2007-08-02 メルク エンド カムパニー インコーポレーテッド 高眼圧の治療のための眼科用組成物
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
US20050148643A1 (en) * 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme
JP4387360B2 (ja) 2003-08-22 2009-12-16 帝人ファーマ株式会社 キマーゼ阻害剤を有効成分として含有する薬剤
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050107374A1 (en) 2003-10-21 2005-05-19 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP4842829B2 (ja) * 2003-10-31 2011-12-21 武田薬品工業株式会社 含窒素縮合複素環化合物
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
US7097961B2 (en) * 2004-05-17 2006-08-29 Agfa Gevaert Stabilizers for use in substantially light-insensitive thermographic recording materials
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗hcv作用を有する縮合ヘテロ環化合物
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
BRPI0517930A (pt) 2004-11-02 2008-10-21 Dsm Ip Assets Bv aditivo para preparações de protetor solar contra uv
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2006078907A1 (en) * 2005-01-20 2006-07-27 Amgen Inc. 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments
WO2006094209A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-benzimidazolylalkyl-substituted amide sirtuin modulators
US7893267B2 (en) 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2007005785A1 (en) * 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator
JPWO2007007463A1 (ja) 2005-07-11 2009-01-29 出光興産株式会社 電子吸引性置換基を有する含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
KR20080028424A (ko) 2005-07-11 2008-03-31 이데미쓰 고산 가부시키가이샤 질소 함유 헤테로환 유도체 및 그것을 사용한 유기전기발광 소자
JP2007039406A (ja) 2005-08-05 2007-02-15 Idemitsu Kosan Co Ltd 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
WO2007064932A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
JP2007153778A (ja) 2005-12-02 2007-06-21 Idemitsu Kosan Co Ltd 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
JP2009525955A (ja) 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
NZ570625A (en) 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2007272795A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
WO2008031016A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of California Heterocyclic ligands for integrin imaging and therapy
EP2088861A4 (en) * 2006-10-25 2010-07-07 Takeda Pharmaceutical Benzimidazole compounds
US20080193796A1 (en) 2006-11-20 2008-08-14 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
RU2009136263A (ru) * 2007-03-02 2011-04-10 Шеринг Корпорейшн (US) Производные бензимидазола и способы их применения
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044056A1 (en) * 2000-11-15 2004-03-04 Osamu Okamoto Benzimidazole derivatives
US20030236267A1 (en) * 2002-05-14 2003-12-25 Kensuke Kobayashi Benzimidazole derivatives
CN1829713A (zh) * 2003-07-30 2006-09-06 辉瑞大药厂 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
guration.《Journal of Pharmaceutical and Biomedical Analysis》.2008, *
Julie Charton et al..Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators.《Bioorganic Medicinal Chemistry》.2006,第14卷 *
Marie-Pierre Vaccher et al..Preparative enantiomeric separation of potent AMP-activated protein kinase activator by HPLC on amylose-based chiral stationary phase Determination of enantiomeric purity and assignment of absolute con#64257 *

Also Published As

Publication number Publication date
WO2010036613A8 (en) 2010-11-18
JP2012503661A (ja) 2012-02-09
CA2737694C (en) 2013-07-02
WO2010036613A1 (en) 2010-04-01
TWI393709B (zh) 2013-04-21
US8394969B2 (en) 2013-03-12
AU2009296820B2 (en) 2014-03-20
US20100081643A1 (en) 2010-04-01
CA2737694A1 (en) 2010-04-01
TW201016672A (en) 2010-05-01
JP5764064B2 (ja) 2015-08-12
AU2009296820A1 (en) 2010-04-01
AR073677A1 (es) 2010-11-24
CN102361857A (zh) 2012-02-22
EP3924343A1 (en) 2021-12-22
MX2011003239A (es) 2011-04-28

Similar Documents

Publication Publication Date Title
CN102361857B (zh) 可用作抗糖尿病剂的环状苯并咪唑衍生物
EP2352374B1 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8895596B2 (en) Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8410284B2 (en) Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN105001219A (zh) 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121031

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: MERCK SHARP & DOHME Corp.

Applicant after: METABASIS THERAPEUTICS, Inc.

Address before: New jersey, USA

Applicant before: SCHERING Corp.

Applicant before: METABASIS THERAPEUTICS, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

TA01 Transfer of patent application right

Effective date of registration: 20121031

Address after: New jersey, USA

Applicant after: SCHERING Corp.

Applicant after: METABASIS THERAPEUTICS, Inc.

Address before: New jersey, USA

Applicant before: MERCK SHARP & DOHME Corp.

Applicant before: METABASIS THERAPEUTICS, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220908

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Patentee after: METABASIS THERAPEUTICS, Inc.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

Patentee before: METABASIS THERAPEUTICS, Inc.